🇺🇸 FDA
Pipeline program

Azacitidin Zentiva 25 mg/ml Pulver zur Herstellung einer Injektionssuspension, Azacitidine 25 mg/mL powder for suspension for injection, SY-1425, Placebo for Tamibarotene (SY-1425), AZACITIDINE

SY-1425-301

Phase 3 small_molecule active

Quick answer

Azacitidin Zentiva 25 mg/ml Pulver zur Herstellung einer Injektionssuspension, Azacitidine 25 mg/mL powder for suspension for injection, SY-1425, Placebo for Tamibarotene (SY-1425), AZACITIDINE for Newly Diagnosed RARA-positive Adult Patients with Higher-risk Myelodysplastic Syndrome is a Phase 3 program (small_molecule) at Pharma Mar S.A. with 1 ClinicalTrials.gov record(s).

Program details

Company
Pharma Mar S.A.
Indication
Newly Diagnosed RARA-positive Adult Patients with Higher-risk Myelodysplastic Syndrome
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials